Filing Details
- Accession Number:
- 0001209191-21-006128
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-29 17:00:09
- Reporting Period:
- 2021-01-27
- Accepted Time:
- 2021-01-29 17:00:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1357874 | Precision Biosciences Inc | DTIL | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1769828 | Derek Jantz | C/O Precision Biosciences, Inc. 302 E. Pettigrew Street, Suite A-100 Durham NC 27701 | Chief Scientific Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-01-27 | 21,514 | $0.04 | 3,884,252 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-01-27 | 7,048 | $11.68 | 3,877,204 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2021-01-28 | 21,514 | $0.04 | 3,898,718 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-01-28 | 6,444 | $11.97 | 3,892,274 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2021-01-27 | 21,514 | $0.00 | 21,514 | $0.04 |
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2021-01-28 | 21,514 | $0.00 | 21,514 | $0.04 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
301,197 | 2021-05-17 | No | 4 | M | Direct | |
279,683 | 2021-05-17 | No | 4 | M | Direct |
Footnotes
- All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares.
- The option is fully vested and exercisable.